CytoSorbents — Third Quarter 2026 Earnings Summary

CytoSorbents Corporation reported third-quarter 2026 revenue of $9.7 million, representing a 3% increase from the prior year, while achieving positive operating cash flow of approximately $43,000 excluding restructuring payments. The company improved its gross margin to 75% and reduced total operating expenses by 11% to $8.5 million, resulting in a net loss of $1.8 million compared to $3.2 million in the same period last year. Management highlighted progress on four strategic value drivers, including sustaining cash flow breakeven, revitalizing the core CytoSorb franchise in Germany, advancing the DrugSorb-ATR submission to the FDA for the U.S. market, and exploring commercial opportunities for the HemoDefend-BGA technology.